| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiation-Protective Agents | 64 | 2017 | 98 | 6.920 |
Why?
|
| Mercaptoethylamines | 44 | 2012 | 52 | 4.530 |
Why?
|
| Amifostine | 38 | 2014 | 50 | 4.050 |
Why?
|
| Superoxide Dismutase | 16 | 2015 | 155 | 2.920 |
Why?
|
| Radiation Tolerance | 23 | 2020 | 179 | 2.480 |
Why?
|
| Cell Survival | 53 | 2018 | 1014 | 1.860 |
Why?
|
| Inhibitor of Apoptosis Proteins | 4 | 2017 | 33 | 1.830 |
Why?
|
| Sulfhydryl Compounds | 11 | 2014 | 67 | 1.560 |
Why?
|
| Fibrosarcoma | 33 | 2016 | 89 | 1.380 |
Why?
|
| NF-kappa B | 8 | 2020 | 423 | 1.250 |
Why?
|
| Dose-Response Relationship, Radiation | 24 | 2018 | 193 | 1.190 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2018 | 461 | 1.150 |
Why?
|
| Reactive Oxygen Species | 7 | 2018 | 525 | 1.080 |
Why?
|
| Neutrons | 18 | 2012 | 57 | 1.040 |
Why?
|
| Repressor Proteins | 3 | 2016 | 447 | 1.030 |
Why?
|
| Cell Cycle | 31 | 2012 | 518 | 0.970 |
Why?
|
| Sarcoma, Experimental | 25 | 2009 | 53 | 0.960 |
Why?
|
| Radiation Injuries, Experimental | 8 | 2014 | 41 | 0.950 |
Why?
|
| Gamma Rays | 28 | 2018 | 72 | 0.830 |
Why?
|
| Metformin | 2 | 2017 | 132 | 0.830 |
Why?
|
| Adaptation, Physiological | 5 | 2015 | 349 | 0.820 |
Why?
|
| Mice, Inbred C3H | 35 | 2017 | 370 | 0.780 |
Why?
|
| Mice | 84 | 2020 | 12698 | 0.760 |
Why?
|
| Animals | 135 | 2020 | 28894 | 0.740 |
Why?
|
| Cricetinae | 38 | 2010 | 533 | 0.720 |
Why?
|
| Acetylcysteine | 7 | 2017 | 73 | 0.720 |
Why?
|
| Mutagenesis | 9 | 2002 | 195 | 0.690 |
Why?
|
| Colonic Neoplasms | 2 | 2018 | 582 | 0.680 |
Why?
|
| Cell Line, Tumor | 14 | 2017 | 2888 | 0.650 |
Why?
|
| CHO Cells | 18 | 2010 | 188 | 0.630 |
Why?
|
| Emodin | 2 | 2017 | 7 | 0.620 |
Why?
|
| Neoplasms, Experimental | 11 | 2017 | 261 | 0.600 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 12 | 1999 | 35 | 0.600 |
Why?
|
| Free Radical Scavengers | 5 | 2014 | 59 | 0.590 |
Why?
|
| DNA Repair | 11 | 2015 | 363 | 0.590 |
Why?
|
| Neoplasms, Radiation-Induced | 11 | 2015 | 96 | 0.580 |
Why?
|
| Endothelial Cells | 5 | 2014 | 500 | 0.580 |
Why?
|
| NADPH Oxidase 4 | 1 | 2018 | 15 | 0.550 |
Why?
|
| DNA Damage | 13 | 2015 | 399 | 0.530 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2011 | 707 | 0.500 |
Why?
|
| Oxidants | 1 | 2016 | 86 | 0.470 |
Why?
|
| Antimutagenic Agents | 4 | 1999 | 7 | 0.460 |
Why?
|
| Gene Expression Regulation | 6 | 2017 | 2023 | 0.450 |
Why?
|
| Organothiophosphorus Compounds | 8 | 2008 | 17 | 0.440 |
Why?
|
| Sarcoma | 2 | 2014 | 222 | 0.430 |
Why?
|
| Histones | 3 | 2007 | 370 | 0.430 |
Why?
|
| Endothelium, Vascular | 5 | 2005 | 440 | 0.430 |
Why?
|
| Glioma | 3 | 2002 | 309 | 0.420 |
Why?
|
| Mutation | 15 | 2018 | 4392 | 0.420 |
Why?
|
| Acute Radiation Syndrome | 1 | 2014 | 1 | 0.420 |
Why?
|
| Micronuclei, Chromosome-Defective | 2 | 2011 | 3 | 0.420 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 1394 | 0.420 |
Why?
|
| Radiation Dosage | 10 | 2017 | 231 | 0.410 |
Why?
|
| Cells, Cultured | 20 | 2014 | 2855 | 0.410 |
Why?
|
| Anticarcinogenic Agents | 3 | 2000 | 71 | 0.400 |
Why?
|
| Tumor Cells, Cultured | 14 | 2018 | 1028 | 0.390 |
Why?
|
| Radiation, Ionizing | 8 | 2015 | 123 | 0.390 |
Why?
|
| Cell Separation | 22 | 1997 | 200 | 0.390 |
Why?
|
| Flow Cytometry | 11 | 2006 | 720 | 0.390 |
Why?
|
| Cytoprotection | 3 | 2002 | 51 | 0.370 |
Why?
|
| Glutathione Peroxidase | 3 | 2009 | 26 | 0.370 |
Why?
|
| Apoptosis | 6 | 2015 | 1752 | 0.360 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2017 | 1950 | 0.360 |
Why?
|
| Cell Proliferation | 2 | 2020 | 1790 | 0.350 |
Why?
|
| Radiotherapy | 2 | 2005 | 325 | 0.340 |
Why?
|
| Radiation Injuries | 3 | 2013 | 160 | 0.340 |
Why?
|
| Catalase | 2 | 2009 | 46 | 0.340 |
Why?
|
| Colorectal Neoplasms | 3 | 2010 | 1103 | 0.320 |
Why?
|
| DNA | 10 | 2006 | 1274 | 0.320 |
Why?
|
| Topoisomerase II Inhibitors | 4 | 2000 | 28 | 0.320 |
Why?
|
| Cell Line | 31 | 2015 | 2483 | 0.310 |
Why?
|
| Cyclophosphamide | 5 | 1999 | 284 | 0.310 |
Why?
|
| Mitochondria | 4 | 2015 | 650 | 0.300 |
Why?
|
| Lung Neoplasms | 14 | 2002 | 2457 | 0.300 |
Why?
|
| DNA Topoisomerases, Type II | 3 | 1998 | 22 | 0.300 |
Why?
|
| Cobalt Radioisotopes | 10 | 1994 | 19 | 0.280 |
Why?
|
| RNA, Small Interfering | 5 | 2016 | 564 | 0.280 |
Why?
|
| Keratinocytes | 4 | 2015 | 156 | 0.280 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2002 | 215 | 0.270 |
Why?
|
| Mice, Inbred C57BL | 10 | 2014 | 3598 | 0.250 |
Why?
|
| Isoenzymes | 2 | 1998 | 272 | 0.250 |
Why?
|
| Radiation-Sensitizing Agents | 5 | 2017 | 98 | 0.250 |
Why?
|
| DNA Breaks | 1 | 2006 | 4 | 0.250 |
Why?
|
| Humans | 53 | 2020 | 98080 | 0.240 |
Why?
|
| Radiation Protection | 1 | 2005 | 26 | 0.220 |
Why?
|
| Phosphorylation | 7 | 2015 | 1145 | 0.220 |
Why?
|
| Neoplasm Transplantation | 11 | 2016 | 399 | 0.210 |
Why?
|
| Cricetulus | 12 | 2010 | 123 | 0.210 |
Why?
|
| Clone Cells | 12 | 2020 | 220 | 0.210 |
Why?
|
| Mesna | 3 | 2014 | 8 | 0.200 |
Why?
|
| Female | 53 | 2020 | 51536 | 0.200 |
Why?
|
| Protective Agents | 2 | 2004 | 34 | 0.200 |
Why?
|
| Captopril | 3 | 2014 | 22 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2017 | 461 | 0.190 |
Why?
|
| Neoplasm Metastasis | 5 | 2002 | 1089 | 0.190 |
Why?
|
| Azacitidine | 2 | 1994 | 152 | 0.180 |
Why?
|
| Radiation Genetics | 4 | 1992 | 7 | 0.180 |
Why?
|
| Transcription, Genetic | 2 | 2020 | 1133 | 0.180 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2002 | 136 | 0.180 |
Why?
|
| Genes, myc | 2 | 2002 | 38 | 0.180 |
Why?
|
| Genomic Instability | 3 | 2012 | 90 | 0.180 |
Why?
|
| Antineoplastic Agents | 5 | 2002 | 2373 | 0.180 |
Why?
|
| Muscle Neoplasms | 1 | 2002 | 16 | 0.180 |
Why?
|
| DNA, Neoplasm | 11 | 1994 | 267 | 0.170 |
Why?
|
| Cell Line, Transformed | 4 | 2014 | 153 | 0.170 |
Why?
|
| Antioxidants | 4 | 2016 | 236 | 0.170 |
Why?
|
| Blotting, Western | 4 | 2015 | 780 | 0.170 |
Why?
|
| Whole-Body Irradiation | 4 | 2015 | 70 | 0.160 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 293 | 0.160 |
Why?
|
| Radiobiology | 2 | 2015 | 15 | 0.160 |
Why?
|
| CD47 Antigen | 1 | 2020 | 26 | 0.160 |
Why?
|
| Colony-Forming Units Assay | 6 | 2014 | 39 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 2 | 2000 | 244 | 0.160 |
Why?
|
| Protein Transport | 3 | 2016 | 448 | 0.150 |
Why?
|
| Interphase | 8 | 1991 | 36 | 0.150 |
Why?
|
| X-Rays | 5 | 2008 | 139 | 0.150 |
Why?
|
| Signal Transduction | 8 | 2020 | 3620 | 0.150 |
Why?
|
| Cell Division | 13 | 2002 | 689 | 0.150 |
Why?
|
| Micronucleus Tests | 3 | 2011 | 5 | 0.150 |
Why?
|
| Hindlimb | 2 | 2016 | 98 | 0.140 |
Why?
|
| Disulfides | 2 | 1997 | 66 | 0.140 |
Why?
|
| Mutagenicity Tests | 2 | 1996 | 6 | 0.140 |
Why?
|
| Centrifugation, Density Gradient | 7 | 1983 | 93 | 0.130 |
Why?
|
| Gene Expression | 1 | 2002 | 1320 | 0.130 |
Why?
|
| Andrographis | 1 | 2017 | 1 | 0.130 |
Why?
|
| Diterpenes | 1 | 2017 | 24 | 0.130 |
Why?
|
| HCT116 Cells | 1 | 2017 | 163 | 0.130 |
Why?
|
| Mutagens | 4 | 1999 | 29 | 0.130 |
Why?
|
| Plant Extracts | 2 | 2017 | 252 | 0.130 |
Why?
|
| In Vitro Techniques | 11 | 2013 | 945 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2013 | 556 | 0.120 |
Why?
|
| CDC2 Protein Kinase | 2 | 2015 | 46 | 0.120 |
Why?
|
| Cycloheximide | 2 | 1995 | 54 | 0.120 |
Why?
|
| Selenium | 1 | 1996 | 46 | 0.120 |
Why?
|
| Lung | 5 | 2011 | 1407 | 0.120 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 1995 | 35 | 0.120 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2015 | 43 | 0.120 |
Why?
|
| Thymidine Kinase | 1 | 1995 | 30 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 8 | 2015 | 1110 | 0.110 |
Why?
|
| Pregnancy | 2 | 2013 | 3244 | 0.110 |
Why?
|
| Enzyme Induction | 3 | 2005 | 83 | 0.110 |
Why?
|
| Oxidation-Reduction | 3 | 2002 | 419 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2015 | 37 | 0.110 |
Why?
|
| Cell Nucleus | 3 | 1994 | 615 | 0.110 |
Why?
|
| Skin | 4 | 2009 | 591 | 0.110 |
Why?
|
| Spermine | 1 | 1994 | 25 | 0.110 |
Why?
|
| DNA-Binding Proteins | 4 | 2010 | 1255 | 0.100 |
Why?
|
| Time Factors | 9 | 2004 | 5567 | 0.100 |
Why?
|
| Misonidazole | 3 | 1984 | 19 | 0.100 |
Why?
|
| Chromosome Deletion | 1 | 1994 | 214 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 110 | 0.100 |
Why?
|
| Blotting, Northern | 3 | 2001 | 239 | 0.100 |
Why?
|
| Ovarian Neoplasms | 5 | 1992 | 825 | 0.100 |
Why?
|
| Genes | 1 | 1994 | 256 | 0.100 |
Why?
|
| Drug Synergism | 1 | 2014 | 317 | 0.100 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 3272 | 0.100 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 86 | 0.100 |
Why?
|
| Hydroxyurea | 3 | 2010 | 233 | 0.100 |
Why?
|
| Mortality, Premature | 1 | 2013 | 6 | 0.100 |
Why?
|
| Cisplatin | 3 | 1986 | 578 | 0.100 |
Why?
|
| Vincristine | 2 | 1983 | 102 | 0.100 |
Why?
|
| Cyclin B1 | 1 | 2012 | 16 | 0.100 |
Why?
|
| Oxygen | 4 | 1996 | 802 | 0.100 |
Why?
|
| Ethylnitrosourea | 1 | 2012 | 30 | 0.090 |
Why?
|
| Alkylating Agents | 1 | 2012 | 32 | 0.090 |
Why?
|
| Cystadenocarcinoma | 2 | 1992 | 12 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 159 | 0.090 |
Why?
|
| Angiostatins | 2 | 2002 | 15 | 0.090 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2013 | 66 | 0.090 |
Why?
|
| Male | 25 | 2014 | 47076 | 0.090 |
Why?
|
| Life Tables | 1 | 1992 | 46 | 0.090 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 159 | 0.090 |
Why?
|
| Nitroimidazoles | 2 | 1984 | 8 | 0.090 |
Why?
|
| Transfection | 4 | 2015 | 883 | 0.090 |
Why?
|
| Plasminogen | 2 | 2002 | 45 | 0.090 |
Why?
|
| Zidovudine | 1 | 1992 | 12 | 0.090 |
Why?
|
| Enzyme Activation | 3 | 2011 | 679 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2013 | 302 | 0.090 |
Why?
|
| Radiation Effects | 3 | 2015 | 25 | 0.090 |
Why?
|
| Chromosome Aberrations | 2 | 1996 | 352 | 0.090 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2011 | 33 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2011 | 22 | 0.090 |
Why?
|
| RNA, Messenger | 4 | 2001 | 2063 | 0.090 |
Why?
|
| Ascites | 1 | 1992 | 55 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2011 | 40 | 0.090 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2004 | 98 | 0.090 |
Why?
|
| Survival Rate | 2 | 2013 | 2041 | 0.090 |
Why?
|
| Misoprostol | 1 | 1991 | 22 | 0.090 |
Why?
|
| Pancreas | 3 | 2009 | 269 | 0.090 |
Why?
|
| Fibroblasts | 3 | 2014 | 767 | 0.080 |
Why?
|
| Genomics | 1 | 2017 | 898 | 0.080 |
Why?
|
| DNA, Single-Stranded | 3 | 1989 | 95 | 0.080 |
Why?
|
| Superoxides | 1 | 2010 | 76 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2015 | 2585 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2002 | 480 | 0.080 |
Why?
|
| Spleen | 3 | 2014 | 375 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 665 | 0.080 |
Why?
|
| Bleomycin | 3 | 1991 | 102 | 0.070 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 1987 | 23 | 0.070 |
Why?
|
| Plasminogen Activators | 1 | 1989 | 10 | 0.070 |
Why?
|
| Genes, p53 | 3 | 2000 | 108 | 0.070 |
Why?
|
| I-kappa B Proteins | 2 | 2009 | 47 | 0.070 |
Why?
|
| Actihaemyl | 1 | 1988 | 1 | 0.070 |
Why?
|
| Tissue Extracts | 1 | 1988 | 24 | 0.070 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 125 | 0.070 |
Why?
|
| Mice, Inbred Strains | 5 | 1992 | 281 | 0.070 |
Why?
|
| Nucleoproteins | 1 | 1988 | 20 | 0.070 |
Why?
|
| Capillary Permeability | 1 | 2008 | 133 | 0.070 |
Why?
|
| Mice, Knockout | 1 | 2013 | 2207 | 0.070 |
Why?
|
| Recombination, Genetic | 1 | 2010 | 423 | 0.070 |
Why?
|
| Plants, Medicinal | 1 | 1987 | 39 | 0.070 |
Why?
|
| Centrifugation | 8 | 1984 | 19 | 0.070 |
Why?
|
| Prostaglandins E, Synthetic | 1 | 1987 | 3 | 0.070 |
Why?
|
| Diatrizoate | 4 | 1976 | 6 | 0.060 |
Why?
|
| MCF-7 Cells | 2 | 2020 | 123 | 0.060 |
Why?
|
| Cell Count | 10 | 1979 | 195 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 1989 | 189 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2009 | 312 | 0.060 |
Why?
|
| Liver | 2 | 2009 | 1231 | 0.060 |
Why?
|
| Mechlorethamine | 1 | 1986 | 10 | 0.060 |
Why?
|
| Electron Spin Resonance Spectroscopy | 4 | 2003 | 337 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2009 | 419 | 0.060 |
Why?
|
| Microcirculation | 1 | 2006 | 101 | 0.060 |
Why?
|
| Oxidative Stress | 3 | 2011 | 489 | 0.060 |
Why?
|
| Sesquiterpenes, Guaiane | 1 | 2005 | 1 | 0.060 |
Why?
|
| G2 Phase | 3 | 1996 | 32 | 0.060 |
Why?
|
| Sesquiterpenes | 1 | 2005 | 13 | 0.060 |
Why?
|
| Panax | 1 | 1987 | 171 | 0.060 |
Why?
|
| Antigens, Neoplasm | 2 | 1998 | 361 | 0.060 |
Why?
|
| Myocardium | 1 | 2009 | 578 | 0.060 |
Why?
|
| Neoplasms | 4 | 2008 | 3334 | 0.060 |
Why?
|
| Kinetics | 4 | 1995 | 1476 | 0.060 |
Why?
|
| Thymidine | 3 | 1981 | 58 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 1992 | 1327 | 0.060 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2004 | 38 | 0.050 |
Why?
|
| Aminoacridines | 1 | 1984 | 1 | 0.050 |
Why?
|
| Carcinogens | 2 | 1999 | 101 | 0.050 |
Why?
|
| Serine | 1 | 2004 | 106 | 0.050 |
Why?
|
| Plasmids | 1 | 2004 | 275 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2002 | 238 | 0.050 |
Why?
|
| Genes, myb | 1 | 2002 | 5 | 0.050 |
Why?
|
| Chemokine CCL5 | 1 | 2002 | 15 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 1987 | 834 | 0.050 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2002 | 38 | 0.050 |
Why?
|
| Hydrogen Peroxide | 2 | 2001 | 173 | 0.050 |
Why?
|
| Receptors, Interleukin | 1 | 2002 | 38 | 0.040 |
Why?
|
| Monokines | 1 | 2002 | 2 | 0.040 |
Why?
|
| ROC Curve | 1 | 2004 | 794 | 0.040 |
Why?
|
| Razoxane | 1 | 2002 | 3 | 0.040 |
Why?
|
| Acrolein | 1 | 2002 | 7 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 1996 | 764 | 0.040 |
Why?
|
| Oxazines | 1 | 2002 | 18 | 0.040 |
Why?
|
| DNA Replication | 1 | 1982 | 169 | 0.040 |
Why?
|
| Glutathione Transferase | 1 | 2002 | 116 | 0.040 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2002 | 48 | 0.040 |
Why?
|
| Doxorubicin | 2 | 1980 | 285 | 0.040 |
Why?
|
| Growth Substances | 1 | 2002 | 79 | 0.040 |
Why?
|
| Pyruvates | 1 | 2001 | 12 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2002 | 85 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2002 | 111 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2001 | 77 | 0.040 |
Why?
|
| Dimerization | 1 | 2001 | 149 | 0.040 |
Why?
|
| Rats | 5 | 2000 | 4071 | 0.040 |
Why?
|
| Prodrugs | 1 | 2001 | 53 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2002 | 184 | 0.040 |
Why?
|
| Macrophages | 3 | 2020 | 643 | 0.040 |
Why?
|
| Tumor Stem Cell Assay | 3 | 1991 | 41 | 0.040 |
Why?
|
| Phagocytosis | 1 | 2020 | 117 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2002 | 582 | 0.040 |
Why?
|
| Body Water | 1 | 1999 | 34 | 0.040 |
Why?
|
| Ovary | 7 | 1989 | 260 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 700 | 0.040 |
Why?
|
| Military Medicine | 1 | 2000 | 26 | 0.040 |
Why?
|
| Catalysis | 1 | 2000 | 216 | 0.040 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 1999 | 17 | 0.040 |
Why?
|
| Amsacrine | 2 | 1992 | 3 | 0.040 |
Why?
|
| Lead Radioisotopes | 2 | 1989 | 6 | 0.040 |
Why?
|
| Molecular Sequence Data | 4 | 1996 | 2896 | 0.040 |
Why?
|
| Drug Design | 1 | 2000 | 135 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2020 | 333 | 0.040 |
Why?
|
| Mitosis | 4 | 1992 | 152 | 0.040 |
Why?
|
| DNA, Kinetoplast | 1 | 1998 | 1 | 0.040 |
Why?
|
| Heart | 1 | 2002 | 527 | 0.040 |
Why?
|
| Cell Extracts | 1 | 1998 | 14 | 0.040 |
Why?
|
| Dithiothreitol | 1 | 1998 | 25 | 0.040 |
Why?
|
| Stereoisomerism | 1 | 1998 | 102 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 1565 | 0.030 |
Why?
|
| Fast Neutrons | 1 | 1978 | 1 | 0.030 |
Why?
|
| Chromatin | 3 | 1990 | 454 | 0.030 |
Why?
|
| gamma-Glutamyltransferase | 3 | 1987 | 17 | 0.030 |
Why?
|
| Methylcholanthrene | 5 | 1983 | 10 | 0.030 |
Why?
|
| Base Sequence | 3 | 1996 | 2222 | 0.030 |
Why?
|
| Protein Kinase C | 3 | 1996 | 267 | 0.030 |
Why?
|
| BALB 3T3 Cells | 1 | 2017 | 1 | 0.030 |
Why?
|
| RNA | 1 | 2002 | 595 | 0.030 |
Why?
|
| Mice, Nude | 3 | 2013 | 830 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 1992 | 839 | 0.030 |
Why?
|
| Ultraviolet Rays | 2 | 1996 | 198 | 0.030 |
Why?
|
| Wasting Syndrome | 1 | 1996 | 3 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 1993 | 1061 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1996 | 67 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 1129 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 1994 | 1105 | 0.030 |
Why?
|
| Down-Regulation | 1 | 1997 | 529 | 0.030 |
Why?
|
| Comet Assay | 1 | 2015 | 8 | 0.030 |
Why?
|
| Fluorocarbons | 1 | 1996 | 64 | 0.030 |
Why?
|
| Bone Marrow | 2 | 2014 | 418 | 0.030 |
Why?
|
| Sex Factors | 2 | 1992 | 1138 | 0.030 |
Why?
|
| Culture Media | 2 | 1992 | 138 | 0.030 |
Why?
|
| RNA, Ribosomal | 1 | 1995 | 66 | 0.030 |
Why?
|
| Thymus Gland | 1 | 1996 | 205 | 0.030 |
Why?
|
| Glutathione Disulfide | 1 | 1995 | 6 | 0.030 |
Why?
|
| Biotransformation | 1 | 1995 | 46 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 1996 | 202 | 0.030 |
Why?
|
| Lens, Crystalline | 1 | 1996 | 67 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 256 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2015 | 34 | 0.030 |
Why?
|
| Models, Biological | 2 | 2020 | 1807 | 0.030 |
Why?
|
| Precancerous Conditions | 2 | 1987 | 218 | 0.030 |
Why?
|
| Idoxuridine | 2 | 1989 | 9 | 0.030 |
Why?
|
| Glutathione | 1 | 1995 | 108 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2015 | 61 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2015 | 86 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2015 | 319 | 0.030 |
Why?
|
| Genes, ras | 1 | 1994 | 97 | 0.030 |
Why?
|
| Cell-Free System | 1 | 1994 | 45 | 0.030 |
Why?
|
| Electroporation | 1 | 1994 | 61 | 0.030 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 1994 | 23 | 0.030 |
Why?
|
| Cysteine | 1 | 1995 | 149 | 0.030 |
Why?
|
| Estrogen Antagonists | 1 | 2013 | 47 | 0.030 |
Why?
|
| Inflammation | 2 | 2011 | 1120 | 0.020 |
Why?
|
| Blood Cells | 1 | 1973 | 32 | 0.020 |
Why?
|
| Cell Aggregation | 2 | 1990 | 37 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 1995 | 895 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2015 | 315 | 0.020 |
Why?
|
| Risk Factors | 2 | 2015 | 6233 | 0.020 |
Why?
|
| Teniposide | 1 | 1992 | 6 | 0.020 |
Why?
|
| Endonucleases | 1 | 1973 | 22 | 0.020 |
Why?
|
| Deoxyribonucleases | 1 | 1973 | 27 | 0.020 |
Why?
|
| Cesium Radioisotopes | 3 | 1978 | 12 | 0.020 |
Why?
|
| Estrogens | 1 | 2013 | 201 | 0.020 |
Why?
|
| Rats, Inbred Strains | 3 | 1989 | 300 | 0.020 |
Why?
|
| Ligands | 1 | 2013 | 486 | 0.020 |
Why?
|
| Etoposide | 1 | 1992 | 207 | 0.020 |
Why?
|
| Culture Techniques | 1 | 1992 | 80 | 0.020 |
Why?
|
| Diploidy | 1 | 1992 | 36 | 0.020 |
Why?
|
| Isoquinolines | 1 | 1992 | 58 | 0.020 |
Why?
|
| S Phase | 1 | 1992 | 64 | 0.020 |
Why?
|
| G1 Phase | 1 | 1992 | 66 | 0.020 |
Why?
|
| Energy Transfer | 2 | 1989 | 25 | 0.020 |
Why?
|
| Aneuploidy | 1 | 1992 | 60 | 0.020 |
Why?
|
| Endothelium | 1 | 2011 | 63 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 131 | 0.020 |
Why?
|
| Life Expectancy | 1 | 1991 | 93 | 0.020 |
Why?
|
| Species Specificity | 1 | 2013 | 690 | 0.020 |
Why?
|
| Corynebacterium | 3 | 1975 | 10 | 0.020 |
Why?
|
| Seminiferous Tubules | 1 | 1990 | 8 | 0.020 |
Why?
|
| Cell Death | 1 | 1992 | 257 | 0.020 |
Why?
|
| Submandibular Gland | 1 | 1990 | 18 | 0.020 |
Why?
|
| Animals, Newborn | 3 | 1987 | 524 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 903 | 0.020 |
Why?
|
| Reference Values | 1 | 1991 | 608 | 0.020 |
Why?
|
| Proteomics | 1 | 2012 | 279 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 922 | 0.020 |
Why?
|
| Free Radicals | 2 | 1991 | 72 | 0.020 |
Why?
|
| Piperazines | 1 | 1992 | 306 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 1984 | 1751 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 1991 | 257 | 0.020 |
Why?
|
| Calcium | 1 | 1994 | 1196 | 0.020 |
Why?
|
| Pyrones | 1 | 2009 | 8 | 0.020 |
Why?
|
| Rad51 Recombinase | 1 | 2010 | 81 | 0.020 |
Why?
|
| Indoles | 1 | 1991 | 334 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2013 | 1391 | 0.020 |
Why?
|
| Morpholines | 1 | 2009 | 67 | 0.020 |
Why?
|
| Camptothecin | 1 | 2010 | 198 | 0.020 |
Why?
|
| Fibrinolysis | 1 | 1989 | 35 | 0.020 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2009 | 65 | 0.020 |
Why?
|
| RNA Interference | 1 | 2010 | 388 | 0.020 |
Why?
|
| Survival Analysis | 1 | 1992 | 1527 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1989 | 239 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2008 | 136 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 1779 | 0.020 |
Why?
|
| Caffeine | 1 | 2009 | 86 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 1610 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 2 | 2003 | 102 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 310 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 2008 | 200 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2008 | 282 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2008 | 313 | 0.020 |
Why?
|
| Adolescent | 1 | 2000 | 10080 | 0.020 |
Why?
|
| Carcinoma | 1 | 1989 | 440 | 0.020 |
Why?
|
| Digestive System | 1 | 1986 | 42 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1992 | 2080 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1987 | 488 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1992 | 1646 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 2 | 1978 | 83 | 0.010 |
Why?
|
| Hematopoietic System | 1 | 2004 | 12 | 0.010 |
Why?
|
| Lymphocytes | 2 | 2001 | 461 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 1992 | 4025 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 1991 | 1088 | 0.010 |
Why?
|
| Central Nervous System | 1 | 2004 | 144 | 0.010 |
Why?
|
| Mitotic Index | 1 | 1983 | 22 | 0.010 |
Why?
|
| Injections, Intravenous | 2 | 1981 | 212 | 0.010 |
Why?
|
| Prognosis | 1 | 1992 | 4116 | 0.010 |
Why?
|
| Methods | 2 | 1973 | 134 | 0.010 |
Why?
|
| Half-Life | 1 | 2003 | 89 | 0.010 |
Why?
|
| Mice, Inbred A | 1 | 1983 | 21 | 0.010 |
Why?
|
| Metronidazole | 1 | 1983 | 26 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1983 | 226 | 0.010 |
Why?
|
| Biological Availability | 1 | 2003 | 86 | 0.010 |
Why?
|
| Gastrointestinal Tract | 1 | 2004 | 198 | 0.010 |
Why?
|
| Transplantation, Homologous | 2 | 1976 | 1026 | 0.010 |
Why?
|
| Epithelium | 2 | 1996 | 316 | 0.010 |
Why?
|
| Ethidium | 2 | 1991 | 13 | 0.010 |
Why?
|
| Guanidines | 1 | 2002 | 34 | 0.010 |
Why?
|
| Zebrafish | 1 | 2004 | 353 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 279 | 0.010 |
Why?
|
| Phenols | 1 | 2002 | 51 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2003 | 674 | 0.010 |
Why?
|
| Kidney | 2 | 2004 | 1123 | 0.010 |
Why?
|
| Cytological Techniques | 1 | 1980 | 30 | 0.010 |
Why?
|
| Cytosol | 1 | 2001 | 193 | 0.010 |
Why?
|
| Adenoma | 1 | 1983 | 260 | 0.010 |
Why?
|
| Cattle | 1 | 2001 | 397 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 380 | 0.010 |
Why?
|
| DNA, Superhelical | 2 | 1990 | 15 | 0.010 |
Why?
|
| Cytarabine | 1 | 1980 | 218 | 0.010 |
Why?
|
| Viscosity | 1 | 1999 | 52 | 0.010 |
Why?
|
| Phosphoramide Mustards | 1 | 1999 | 5 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2001 | 557 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1986 | 831 | 0.010 |
Why?
|
| Fluorometry | 1 | 1978 | 30 | 0.010 |
Why?
|
| Bacterial Vaccines | 2 | 1975 | 44 | 0.010 |
Why?
|
| Chromosomes | 1 | 1977 | 91 | 0.010 |
Why?
|
| Hypoxia | 1 | 1983 | 699 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 993 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1996 | 26 | 0.010 |
Why?
|
| Diethylnitrosamine | 2 | 1987 | 7 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1996 | 157 | 0.010 |
Why?
|
| Phenotype | 2 | 1996 | 2638 | 0.010 |
Why?
|
| Hydrocarbons, Brominated | 1 | 1996 | 4 | 0.010 |
Why?
|
| Partial Pressure | 1 | 1996 | 47 | 0.010 |
Why?
|
| Cyclic N-Oxides | 1 | 1996 | 32 | 0.010 |
Why?
|
| Erythrocytes | 2 | 1975 | 242 | 0.010 |
Why?
|
| Spin Labels | 1 | 1996 | 107 | 0.010 |
Why?
|
| Iron | 2 | 1987 | 178 | 0.010 |
Why?
|
| Oximetry | 1 | 1996 | 94 | 0.010 |
Why?
|
| Linear Energy Transfer | 1 | 1994 | 5 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1994 | 28 | 0.010 |
Why?
|
| Nuclear Reactors | 1 | 1994 | 7 | 0.010 |
Why?
|
| Rabbits | 1 | 1996 | 581 | 0.010 |
Why?
|
| Codon | 1 | 1994 | 116 | 0.010 |
Why?
|
| Egtazic Acid | 1 | 1994 | 32 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 1994 | 34 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 1974 | 28 | 0.010 |
Why?
|
| Epidermis | 1 | 1994 | 106 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 1975 | 269 | 0.010 |
Why?
|
| Muscular Atrophy | 1 | 1994 | 49 | 0.010 |
Why?
|
| Amino Sugars | 1 | 1974 | 2 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 1974 | 47 | 0.010 |
Why?
|
| Tritium | 1 | 1974 | 113 | 0.010 |
Why?
|
| Sorbitol | 1 | 1974 | 9 | 0.010 |
Why?
|
| Chelating Agents | 1 | 1994 | 68 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 1994 | 269 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1973 | 244 | 0.010 |
Why?
|
| Electrophoresis, Disc | 1 | 1973 | 13 | 0.010 |
Why?
|
| Microchemistry | 1 | 1973 | 6 | 0.010 |
Why?
|
| Exonucleases | 1 | 1973 | 11 | 0.010 |
Why?
|
| DNA, Circular | 1 | 1973 | 11 | 0.010 |
Why?
|
| Vaccination | 1 | 1975 | 323 | 0.010 |
Why?
|
| Novobiocin | 1 | 1992 | 1 | 0.010 |
Why?
|
| Aphidicolin | 1 | 1992 | 4 | 0.010 |
Why?
|
| Melanins | 1 | 1992 | 24 | 0.010 |
Why?
|
| Deoxyadenosines | 1 | 1992 | 23 | 0.010 |
Why?
|
| Actins | 1 | 1996 | 480 | 0.010 |
Why?
|
| Bacteriophages | 1 | 1973 | 45 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1992 | 198 | 0.010 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1992 | 36 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1973 | 238 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 1996 | 709 | 0.010 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1992 | 177 | 0.010 |
Why?
|
| Cells | 1 | 1991 | 30 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 1994 | 521 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 2005 | 0.010 |
Why?
|
| Peptides | 1 | 1994 | 669 | 0.010 |
Why?
|
| Contrast Media | 1 | 1975 | 1011 | 0.010 |
Why?
|
| Keratins | 1 | 1989 | 62 | 0.000 |
Why?
|
| Carcinoma, Ehrlich Tumor | 1 | 1989 | 7 | 0.000 |
Why?
|
| Immunotherapy | 1 | 1975 | 819 | 0.000 |
Why?
|
| Nucleic Acid Conformation | 1 | 1989 | 348 | 0.000 |
Why?
|
| Transplantation, Heterologous | 1 | 1989 | 375 | 0.000 |
Why?
|
| Receptors, Estrogen | 1 | 1989 | 428 | 0.000 |
Why?
|
| Lethal Dose 50 | 1 | 1986 | 8 | 0.000 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 1975 | 43 | 0.000 |
Why?
|
| Ascitic Fluid | 2 | 1975 | 36 | 0.000 |
Why?
|
| Mathematics | 1 | 1984 | 176 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1996 | 3606 | 0.000 |
Why?
|
| Stem Cells | 1 | 1986 | 396 | 0.000 |
Why?
|
| Radiotherapy Dosage | 1 | 1983 | 479 | 0.000 |
Why?
|
| Centrifugation, Isopycnic | 1 | 1979 | 4 | 0.000 |
Why?
|
| Transplantation, Isogeneic | 1 | 1977 | 38 | 0.000 |
Why?
|
| Trypsin | 1 | 1975 | 92 | 0.000 |
Why?
|
| Injections, Subcutaneous | 1 | 1975 | 141 | 0.000 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1975 | 130 | 0.000 |
Why?
|
| Melanoma | 1 | 1975 | 524 | 0.000 |
Why?
|
| Middle Aged | 1 | 1989 | 29428 | 0.000 |
Why?
|